Ascentage Pharma Announces Board Meeting
Ticker: AAPG · Form: 6-K · Filed: Aug 8, 2025 · CIK: 2023311
Sentiment: neutral
Topics: board-meeting, disclosure
TL;DR
Ascentage Pharma board meeting scheduled for Aug 8, 2025 - expect news soon.
AI Summary
Ascentage Pharma Group International announced on August 8, 2025, that its Board of Directors will hold a meeting. The purpose of the meeting is not specified in this filing, but it is a routine disclosure for companies listed on the Hong Kong Stock Exchange.
Why It Matters
This filing indicates a scheduled board meeting, which could precede significant corporate announcements or decisions regarding the company's operations or financial performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of a board meeting, not an announcement of material events or financial results.
Key Players & Entities
- Ascentage Pharma Group International (company) — Filer of the report
- August 8, 2025 (date) — Date of the announcement and board meeting
FAQ
What is the purpose of the board meeting announced by Ascentage Pharma Group International?
The specific purpose of the board meeting scheduled for August 8, 2025, is not disclosed in this Form 6-K filing.
Where did Ascentage Pharma Group International post this announcement?
Ascentage Pharma Group International posted the announcement on the Hong Kong Stock Exchange.
What is the filing type and date?
This is a Form 6-K filed on August 8, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Is Ascentage Pharma Group International required to file Form 20-F or 40-F annually?
Ascentage Pharma Group International indicates it files annual reports under cover of Form 20-F.
Filing Stats: 192 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2025-08-08 16:15:06
Filing Documents
- ea025244901-6k_ascentage.htm (6-K) — 10KB
- ea025244901ex99-1_ascentage.htm (EX-99.1) — 5KB
- image_003.jpg (GRAPHIC) — 5KB
- 0001213900-25-073669.txt ( ) — 23KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On August 8, 2025, Ascentage Pharma Group International posted an announcement on the Hong Kong Stock Exchange entitled, “Notice of Board Meeting”. A copy of the announcement is furnished as Exhibit 99.1 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Announcement dated August 8, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: August 8, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3